undamentalytics Newsletter
Sign in

Bone Biologics Corp key statistics and ratios

In fiscal 2020, Bone Biologics Corp had a net margin of -0.2%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162019Dec 20192020Dec 2020LTMJun 2021
Net margin−2.4%−0.3%−0.2%−0.2%
Return on assets<−999%−935.8%<−999%<−999%
R&D as % of revenue1.0%0.1%0.0%0.0%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Bone Biologics Corp's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bone Biologics Corp.